Molecular Recognition at Purine and Pyrimidine Nucleotide (P2) Receptors

Overview

Journal Curr Top Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2004 Apr 14

PMID 15078212

Citations 30

Authors

Kenneth A Jacobson

Stefano Costanzi

Michihiro Ohno

Bhalchandra V Joshi

Pedro Besada

Bin Xu

Susanna Tchilibon

Affiliations

Soon will be listed here.

Abstract

In comparison to other classes of cell surface receptors, the medicinal chemistry at P2X (ligand-gated ion channels) and P2Y (G protein-coupled) nucleotide receptors has been relatively slow to develop. Recent effort to design selective agonists and antagonists based on a combination of library screening, empirical modification of known ligands, and rational design have led to the introduction of potent antagonists of the P2X(1) (derivatives of pyridoxal phosphates and suramin), P2X(3)(A-317491), P2X(7) (derivatives of the isoquinoline KN-62), P2Y(1)(nucleotide analogues MRS 2179 and MRS 2279), P2Y(2)(thiouracil derivatives such as AR-C126313), and P2Y(12)(nucleotide/nucleoside analogues AR-C69931X and AZD6140) receptors. A variety of native agonist ligands (ATP, ADP, UTP, UDP, and UDP-glucose) are currently the subject of structural modification efforts to improve selectivity. MRS2365 is a selective agonist for P2Y(1)receptors. The dinucleotide INS 37217 potently activates the P2Y(2)receptor. UTP-gamma-S and UDP-beta-S are selective agonists for P2Y(2)/P2Y(4)and P2Y(6)receptors, respectively. The current knowledge of the structures of P2X and P2Y receptors, is derived mainly from mutagenesis studies. Site-directed mutagenesis has shown that ligand recognition in the human P2Y(1)receptor involves individual residues of both the TMs (3, 5, 6, and 7), as well as EL 2 and 3. The binding of the negatively-charged phosphate moiety is dependent on positively charged lysine and arginine residues near the exofacial side of TMs 3 and 7.

Citing Articles

Purinergic system in cancer stem cells.

Nunez-Rios J, Ulrich H, Diaz-Munoz M, Lameu C, Vazquez-Cuevas F Purinergic Signal. 2023; 21(1):23-38.

PMID: 37966629 PMC: 11904000. DOI: 10.1007/s11302-023-09976-5.

Role of the Purinergic P2Y2 Receptor in Pulmonary Hypertension.

Shihan M, Novoyatleva T, Lehmeyer T, Sydykov A, Schermuly R Int J Environ Res Public Health. 2021; 18(21).

PMID: 34769531 PMC: 8582672. DOI: 10.3390/ijerph182111009.

Neurotransmitters responsible for purinergic motor neurotransmission and regulation of GI motility.

Sanders K, Mutafova-Yambolieva V Auton Neurosci. 2021; 234:102829.

PMID: 34146957 PMC: 8575072. DOI: 10.1016/j.autneu.2021.102829.

Modulating pyrimidine ribonucleotide levels for the treatment of cancer.

Mollick T, Lain S Cancer Metab. 2020; 8:12.

PMID: 33020720 PMC: 7285601. DOI: 10.1186/s40170-020-00218-5.

Quality Evaluation of Based on the Nucleic Acid Compounds by UPLC-TOF/MS and UPLC-QqQ/MS.

Xue Y, Jin W, Xu X, Yong L, Hu B, Xiong J Molecules. 2018; 24(1).

PMID: 30583462 PMC: 6337655. DOI: 10.3390/molecules24010034.

References

Chen W, Ravi R, Kertesy S, Dubyak G, Jacobson K . Functionalized congeners of tyrosine-based P2X(7) receptor antagonists: probing multiple sites for linking and dimerization. Bioconjug Chem. 2002; 13(5):1100-11. PMC: 5577561. DOI: 10.1021/bc020025i. View

Pendergast W, Yerxa B, Douglass 3rd J, Shaver S, DOUGHERTY R, Redick C . Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates. Bioorg Med Chem Lett. 2001; 11(2):157-60. DOI: 10.1016/s0960-894x(00)00612-0. View

Ravi R, Kim H, Servos J, Zimmermann H, Lee K, Maddileti S . Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem. 2002; 45(10):2090-100. PMC: 4959107. DOI: 10.1021/jm010538v. View

Diaz-Hernandez M, Pintor J, Miras-Portugal M . Modulation of the dinucleotide receptor present in rat midbrain synaptosomes by adenosine and ATP. Br J Pharmacol. 2000; 130(2):434-40. PMC: 1572065. DOI: 10.1038/sj.bjp.0703300. View

Fischer B, Boyer J, Hoyle C, Ziganshin A, Brizzolara A, Knight G . Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5'-triphosphate. J Med Chem. 1993; 36(24):3937-46. PMC: 4431635. DOI: 10.1021/jm00076a023. View

Lambrecht G . Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(4-5):340-50. DOI: 10.1007/s002100000312. View

Xu B, Stephens A, Kirschenheuter G, Greslin A, Cheng X, Sennelo J . Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem. 2002; 45(26):5694-709. PMC: 9233741. DOI: 10.1021/jm020173u. View

Erb L, Garrad R, Wang Y, Quinn T, Turner J, Weisman G . Site-directed mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane helices 6 and 7 affect agonist potency and specificity. J Biol Chem. 1995; 270(9):4185-8. DOI: 10.1074/jbc.270.9.4185. View

Spelta V, Jiang L, Surprenant A, North R . Kinetics of antagonist actions at rat P2X2/3 heteromeric receptors. Br J Pharmacol. 2002; 135(6):1524-30. PMC: 1573256. DOI: 10.1038/sj.bjp.0704591. View

10.

Khakh B, Burnstock G, Kennedy C, King B, North R, Seguela P . International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev. 2001; 53(1):107-18. View

11.

von Kugelgen I, Wetter A . Molecular pharmacology of P2Y-receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(4-5):310-23. DOI: 10.1007/s002100000310. View

12.

Malmsjo M, Adner M, Harden T, Pendergast W, Edvinsson L, Erlinge D . The stable pyrimidines UDPbetaS and UTPgammaS discriminate between the P2 receptors that mediate vascular contraction and relaxation of the rat mesenteric artery. Br J Pharmacol. 2000; 131(1):51-6. PMC: 1572295. DOI: 10.1038/sj.bjp.0703536. View

13.

Boyer J, Adams M, Ravi R, Jacobson K, Harden T . 2-Chloro N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate is a selective high affinity P2Y(1) receptor antagonist. Br J Pharmacol. 2002; 135(8):2004-10. PMC: 1573330. DOI: 10.1038/sj.bjp.0704673. View

14.

Abbracchio M, Boeynaems J, Barnard E, Boyer J, Kennedy C, Miras-Portugal M . Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family. Trends Pharmacol Sci. 2003; 24(2):52-5. PMC: 8653507. DOI: 10.1016/S0165-6147(02)00038-X. View

15.

Kim Y, Brown S, Harden T, Boyer J, Dubyak G, King B . Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors. J Med Chem. 2001; 44(3):340-9. PMC: 10790710. DOI: 10.1021/jm9904203. View

16.

Raboisson P, Baurand A, Cazenave J, Gachet C, Schultz D, Spiess B . A general approach toward the synthesis of C-nucleoside pyrazolo[1,5-a]-1,3,5-triazines and their 3',5'-bisphosphate C-nucleotide analogues as the first reported in vivo stable P2Y(1)-receptor antagonists. J Org Chem. 2002; 67(23):8063-71. DOI: 10.1021/jo026268l. View

17.

Sugidachi A, Asai F, Yoneda K, Iwamura R, Ogawa T, Otsuguro K . Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747. Br J Pharmacol. 2001; 132(1):47-54. PMC: 1572523. DOI: 10.1038/sj.bjp.0703761. View

18.

Muller C . P2-pyrimidinergic receptors and their ligands. Curr Pharm Des. 2002; 8(26):2353-69. DOI: 10.2174/1381612023392937. View

19.

Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H . Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des. 2002; 8(26):2371-99. DOI: 10.2174/1381612023392973. View

20.

Lee D, Nguyen T, Lynch K, Cheng R, Vanti W, Arkhitko O . Discovery and mapping of ten novel G protein-coupled receptor genes. Gene. 2001; 275(1):83-91. DOI: 10.1016/s0378-1119(01)00651-5. View